Transforming New Parts for People with X-Therma

Aging takes a treacherous toll on the body and its organs. Methuselah Foundation aims to build a future where replacing biological parts is as simple as replacing parts on a modern car.

Photo Credit: X-Therma Inc.

We are excited to announce that Methuselah Foundation invested in X-Therma Inc. - a biotechnology company developing breakthroughs for regenerative medicine and organ preservation - who closed an oversubscribed $13M Series A funding round.

The financing is led by LOREA AG, an entrepreneur-operated investment firm, with participation from Zen11 Holdings, Graphene Ventures, VU Venture Partners, 2b AHEAD Ventures, Catalytic Impact Foundation, along with notable return angel investors.

X-Therma demonstrated a significant extension of organ shelf-life from just a few hours to a few days in collaboration with world-leading surgeon, Dr. Gerald Brandacher from Johns Hopkins University.

“We’re excited about the transformative impact of X-Therma’s technology and potential to better meet society’s demands of safely and successfully transplanting organs across the globe,” says Dr. Christoph Swarovski, owner and founder of LOREA AG. “Our conviction in this technology was inspired by the world’s dire need of a better solution for organ transport and we are fortunate to help X-Therma bring its vision to fruition.”

“Founded with the mission to enable global organ banking, our platform technology has expanded to all living medicines. Biopreservation is crucial in the evolving regenerative medicine market. It underlies the sourcing of cellular material, manufacture, storage, and delivery of final products,” says Dr. Xiaoxi Wei, CEO & Co-Founder of X-Therma.

“Since the onset of the pandemic, the demand for advanced biopharma cold chain solutions has become extremely hot. COVID vaccines have accelerated this growth and exposed cold-chain weaknesses. From day one, our vision has been focused on the heavy lifting of fundamental scientific breakthroughs to solve the soon-to-be bottlenecks still in existence due to a lack of innovation. Our technology supports cell and gene therapy CMC by greatly improving the critical cell preservation process that can make-or-break the delivery of a successful medicine.” 

Read X-Therma’s press release here.